![Postoperative fondaparinux versus preoperative enoxaparin for prevention of venous thromboembolism in elective hip-replacement surgery: a randomised double-blind comparison - The Lancet Postoperative fondaparinux versus preoperative enoxaparin for prevention of venous thromboembolism in elective hip-replacement surgery: a randomised double-blind comparison - The Lancet](https://www.thelancet.com/cms/attachment/2119418791/2093590429/gr1.gif)
Postoperative fondaparinux versus preoperative enoxaparin for prevention of venous thromboembolism in elective hip-replacement surgery: a randomised double-blind comparison - The Lancet
![Natural killer cells and immune-checkpoint inhibitor therapy: Current knowledge and new challenges: Molecular Therapy - Oncolytics Natural killer cells and immune-checkpoint inhibitor therapy: Current knowledge and new challenges: Molecular Therapy - Oncolytics](https://www.cell.com/cms/attachment/cb8f8e60-9a4d-44df-a8df-f8cde148c9df/fx1_lrg.jpg)
Natural killer cells and immune-checkpoint inhibitor therapy: Current knowledge and new challenges: Molecular Therapy - Oncolytics
![Internal mammary and medial supraclavicular lymph node chain irradiation in stage I–III breast cancer (EORTC 22922/10925): 15-year results of a randomised, phase 3 trial - The Lancet Oncology Internal mammary and medial supraclavicular lymph node chain irradiation in stage I–III breast cancer (EORTC 22922/10925): 15-year results of a randomised, phase 3 trial - The Lancet Oncology](https://www.thelancet.com/cms/attachment/cde48173-5488-4d33-bae0-b205859d61aa/gr3.jpg)
Internal mammary and medial supraclavicular lymph node chain irradiation in stage I–III breast cancer (EORTC 22922/10925): 15-year results of a randomised, phase 3 trial - The Lancet Oncology
![Cells | Free Full-Text | Photosynthesis in Response to Different Salinities and Immersions of Two Native Rhizophoraceae Mangroves Cells | Free Full-Text | Photosynthesis in Response to Different Salinities and Immersions of Two Native Rhizophoraceae Mangroves](https://www.mdpi.com/cells/cells-11-03054/article_deploy/html/images/cells-11-03054-g001.png)
Cells | Free Full-Text | Photosynthesis in Response to Different Salinities and Immersions of Two Native Rhizophoraceae Mangroves
![Rucaparib versus standard-of-care chemotherapy in patients with relapsed ovarian cancer and a deleterious BRCA1 or BRCA2 mutation (ARIEL4): an international, open-label, randomised, phase 3 trial - The Lancet Oncology Rucaparib versus standard-of-care chemotherapy in patients with relapsed ovarian cancer and a deleterious BRCA1 or BRCA2 mutation (ARIEL4): an international, open-label, randomised, phase 3 trial - The Lancet Oncology](https://www.thelancet.com/cms/asset/ebf9c17b-7269-4c6d-ba49-4dad8ba06853/gr1.jpg)
Rucaparib versus standard-of-care chemotherapy in patients with relapsed ovarian cancer and a deleterious BRCA1 or BRCA2 mutation (ARIEL4): an international, open-label, randomised, phase 3 trial - The Lancet Oncology
![The clinical and cost-effectiveness of total versus partial knee replacement in patients with medial compartment osteoarthritis (TOPKAT): 5-year outcomes of a randomised controlled trial - The Lancet The clinical and cost-effectiveness of total versus partial knee replacement in patients with medial compartment osteoarthritis (TOPKAT): 5-year outcomes of a randomised controlled trial - The Lancet](https://www.thelancet.com/cms/attachment/e89444fa-6fea-4e2b-8882-3f9886e16e3a/gr1.gif)
The clinical and cost-effectiveness of total versus partial knee replacement in patients with medial compartment osteoarthritis (TOPKAT): 5-year outcomes of a randomised controlled trial - The Lancet
![Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial - The Lancet Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial - The Lancet](https://www.thelancet.com/cms/attachment/2001012279/2003803955/gr1.gif)
Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial - The Lancet
![Solid-State NMR Investigations of Extracellular Matrixes and Cell Walls of Algae, Bacteria, Fungi, and Plants | Chemical Reviews Solid-State NMR Investigations of Extracellular Matrixes and Cell Walls of Algae, Bacteria, Fungi, and Plants | Chemical Reviews](https://pubs.acs.org/cms/10.1021/acs.chemrev.1c00669/asset/images/large/cr1c00669_0024.jpeg)
Solid-State NMR Investigations of Extracellular Matrixes and Cell Walls of Algae, Bacteria, Fungi, and Plants | Chemical Reviews
![Amazon.com: Mini VCI J2534 Tis Techstream Cable OBD2 Diagnostic Cable for Supporting TIS Techstream : Automotive Amazon.com: Mini VCI J2534 Tis Techstream Cable OBD2 Diagnostic Cable for Supporting TIS Techstream : Automotive](https://images-na.ssl-images-amazon.com/images/I/61NRkT39nrL._AC_UL900_SR615,900_.jpg)
Amazon.com: Mini VCI J2534 Tis Techstream Cable OBD2 Diagnostic Cable for Supporting TIS Techstream : Automotive
![Rituximab versus intravenous cyclophosphamide in patients with connective tissue disease-associated interstitial lung disease in the UK (RECITAL): a double-blind, double-dummy, randomised, controlled, phase 2b trial - The Lancet Respiratory Medicine Rituximab versus intravenous cyclophosphamide in patients with connective tissue disease-associated interstitial lung disease in the UK (RECITAL): a double-blind, double-dummy, randomised, controlled, phase 2b trial - The Lancet Respiratory Medicine](https://www.thelancet.com/cms/asset/630466b7-fd95-4f78-b8cc-b5413cd50be5/gr1.jpg)
Rituximab versus intravenous cyclophosphamide in patients with connective tissue disease-associated interstitial lung disease in the UK (RECITAL): a double-blind, double-dummy, randomised, controlled, phase 2b trial - The Lancet Respiratory Medicine
![Antibody-mediated allograft rejection is associated with an increase in peripheral differentiated CD28-CD8+ T cells – Analyses of a cohort of 1032 kidney transplant recipients - eBioMedicine Antibody-mediated allograft rejection is associated with an increase in peripheral differentiated CD28-CD8+ T cells – Analyses of a cohort of 1032 kidney transplant recipients - eBioMedicine](https://www.thelancet.com/cms/attachment/db84faa2-8ed4-4c60-b28b-bb4784a52754/gr1.jpg)
Antibody-mediated allograft rejection is associated with an increase in peripheral differentiated CD28-CD8+ T cells – Analyses of a cohort of 1032 kidney transplant recipients - eBioMedicine
![LncRNA Osilr9 coordinates promoter DNA demethylation and the intrachromosomal loop structure required for maintaining stem cell pluripotency: Molecular Therapy LncRNA Osilr9 coordinates promoter DNA demethylation and the intrachromosomal loop structure required for maintaining stem cell pluripotency: Molecular Therapy](https://www.cell.com/cms/attachment/0603a654-9e8b-47e8-bc3d-7bc946e4da7e/fx1_lrg.jpg)
LncRNA Osilr9 coordinates promoter DNA demethylation and the intrachromosomal loop structure required for maintaining stem cell pluripotency: Molecular Therapy
![Enforced expression of Runx3 improved CAR-T cell potency in solid tumor via enhancing resistance to activation-induced cell death: Molecular Therapy Enforced expression of Runx3 improved CAR-T cell potency in solid tumor via enhancing resistance to activation-induced cell death: Molecular Therapy](https://www.cell.com/cms/attachment/e31f02dc-20fe-47bd-a581-9a7500b80221/fx1_lrg.jpg)
Enforced expression of Runx3 improved CAR-T cell potency in solid tumor via enhancing resistance to activation-induced cell death: Molecular Therapy
![Patient-reported outcomes with durvalumab after chemoradiotherapy in stage III, unresectable non-small-cell lung cancer (PACIFIC): a randomised, controlled, phase 3 study - The Lancet Oncology Patient-reported outcomes with durvalumab after chemoradiotherapy in stage III, unresectable non-small-cell lung cancer (PACIFIC): a randomised, controlled, phase 3 study - The Lancet Oncology](https://www.thelancet.com/cms/asset/a10175b4-7e68-4d5f-a894-92a1f3574549/gr1.jpg)
Patient-reported outcomes with durvalumab after chemoradiotherapy in stage III, unresectable non-small-cell lung cancer (PACIFIC): a randomised, controlled, phase 3 study - The Lancet Oncology
![Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial - The Lancet Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial - The Lancet](https://www.thelancet.com/cms/asset/5e841db0-b227-4831-9b90-4396dd1f0f99/gr1.jpg)
Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial - The Lancet
![Exons 45–55 Skipping Using Mutation-Tailored Cocktails of Antisense Morpholinos in the DMD Gene: Molecular Therapy Exons 45–55 Skipping Using Mutation-Tailored Cocktails of Antisense Morpholinos in the DMD Gene: Molecular Therapy](https://www.cell.com/cms/attachment/92be8dd2-967d-4526-8b86-15cd52aa6ed2/fx1.jpg)
Exons 45–55 Skipping Using Mutation-Tailored Cocktails of Antisense Morpholinos in the DMD Gene: Molecular Therapy
![Temozolomide chemotherapy versus radiotherapy in high-risk low-grade glioma (EORTC 22033-26033): a randomised, open-label, phase 3 intergroup study - The Lancet Oncology Temozolomide chemotherapy versus radiotherapy in high-risk low-grade glioma (EORTC 22033-26033): a randomised, open-label, phase 3 intergroup study - The Lancet Oncology](https://www.thelancet.com/cms/attachment/9eb7b8d2-2daa-424c-91a9-73a87cc1c2a5/gr1.gif)
Temozolomide chemotherapy versus radiotherapy in high-risk low-grade glioma (EORTC 22033-26033): a randomised, open-label, phase 3 intergroup study - The Lancet Oncology
![Lisocabtagene maraleucel versus standard of care with salvage chemotherapy followed by autologous stem cell transplantation as second-line treatment in patients with relapsed or refractory large B-cell lymphoma (TRANSFORM): results from an interim Lisocabtagene maraleucel versus standard of care with salvage chemotherapy followed by autologous stem cell transplantation as second-line treatment in patients with relapsed or refractory large B-cell lymphoma (TRANSFORM): results from an interim](https://www.thelancet.com/cms/attachment/307e4943-ccdd-4bd9-b9a0-68874d1a3f4c/gr1.gif)
Lisocabtagene maraleucel versus standard of care with salvage chemotherapy followed by autologous stem cell transplantation as second-line treatment in patients with relapsed or refractory large B-cell lymphoma (TRANSFORM): results from an interim
![Frontiers | Prediction, prevention, and management of right ventricular failure after left ventricular assist device implantation: A comprehensive review Frontiers | Prediction, prevention, and management of right ventricular failure after left ventricular assist device implantation: A comprehensive review](https://www.frontiersin.org/files/Articles/1040251/fcvm-09-1040251-HTML-r1/image_m/fcvm-09-1040251-g001.jpg)
Frontiers | Prediction, prevention, and management of right ventricular failure after left ventricular assist device implantation: A comprehensive review
![Late Effects of Severe Acute Graft-versus-Host Disease on Quality of Life, Medical Comorbidities, and Survival - Transplantation and Cellular Therapy, Official Publication of the American Society for Transplantation and Cellular Therapy Late Effects of Severe Acute Graft-versus-Host Disease on Quality of Life, Medical Comorbidities, and Survival - Transplantation and Cellular Therapy, Official Publication of the American Society for Transplantation and Cellular Therapy](https://www.astctjournal.org/cms/attachment/c078ca22-72aa-463b-ade0-411091c75a6d/gr1.jpg)
Late Effects of Severe Acute Graft-versus-Host Disease on Quality of Life, Medical Comorbidities, and Survival - Transplantation and Cellular Therapy, Official Publication of the American Society for Transplantation and Cellular Therapy
Chemical Transformations of Biomass-Derived C6-Furanic Platform Chemicals for Sustainable Energy Research, Materials Science, and Synthetic Building Blocks | ACS Sustainable Chemistry & Engineering
![IJMS | Free Full-Text | Investigation of the Fuzzy Complex between RSV Nucleoprotein and Phosphoprotein to Optimize an Inhibition Assay by Fluorescence Polarization IJMS | Free Full-Text | Investigation of the Fuzzy Complex between RSV Nucleoprotein and Phosphoprotein to Optimize an Inhibition Assay by Fluorescence Polarization](https://www.mdpi.com/ijms/ijms-24-00569/article_deploy/html/images/ijms-24-00569-g001.png)
IJMS | Free Full-Text | Investigation of the Fuzzy Complex between RSV Nucleoprotein and Phosphoprotein to Optimize an Inhibition Assay by Fluorescence Polarization
![Seven days treatment with the angiotensin II type 2 receptor agonist C21 in hospitalized COVID-19 patients; a placebo-controlled randomised multi-centre double-blind phase 2 trial - eClinicalMedicine Seven days treatment with the angiotensin II type 2 receptor agonist C21 in hospitalized COVID-19 patients; a placebo-controlled randomised multi-centre double-blind phase 2 trial - eClinicalMedicine](https://www.thelancet.com/cms/attachment/beb6cd03-a35a-4332-bf2d-1522a26a6d12/gr1.jpg)
Seven days treatment with the angiotensin II type 2 receptor agonist C21 in hospitalized COVID-19 patients; a placebo-controlled randomised multi-centre double-blind phase 2 trial - eClinicalMedicine
![National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: IV. The 2020 Highly morbid forms report - Transplantation and Cellular Therapy, Official Publication of the National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: IV. The 2020 Highly morbid forms report - Transplantation and Cellular Therapy, Official Publication of the](https://www.astctjournal.org/cms/attachment/30e65a53-ac5f-4934-8728-285682532547/gr1_lrg.jpg)
National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: IV. The 2020 Highly morbid forms report - Transplantation and Cellular Therapy, Official Publication of the
![Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 ... Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 ...](https://www.thelancet.com/cms/attachment/93c792df-ed55-48cd-905b-99101c6f5324/gr1.gif)